The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Join ShareProphets at less than 2p per article

> Hot share tips

> All the big AIM fraud exposés

> 300 articles and podcasts a month

> Original investigations by our experienced team

> No ads, no click-bait, no auto-play videos

Find out more

SweetBiotix® development: Results of human taste study: more good news from Optibiotix but no SMTM Moment

By HotStockRockets | Thursday 13 July 2017

Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Optibiotix (OPTI) has announced the success of human taste studies in its SweetBiotix® product development programme. The programme has been designed to develop sweet natural healthy fibres, called SweetBiotix®, which are not digested in the human gut, and hence calorie free.

The study was carried out by The Flavour and Sensory Science Centre at the University of Reading who tested six customised oligosaccharides developed from high intensity sweeteners which were compared to sucrose. The study used a trained expert panel of ten experienced panellists and showed:-

The customised oligosaccharides showed sweetness of between 140X and 223X that of sucrose at equivalent concentrations

Customised oligosaccharides derived from Stevia showed a large reduction in bitterness whilst not affecting its sweetness

The results of this independent study provide proof of product concept for a natural, low calorie, SweetBiotix®. This is an innovative concept which has the potential to address public health concerns over the impact of sugar on obesity, with the prospect of replacing 'unhealthy' sugars in existing products with low calorie, healthy non-digestible fibres, trademarked as SweetBiotix®.

Great that all sounds fabbo but there is no SMTM (Show Me The Money) moment. we are told that this market globally is forecast to reach $112 billion by 2022 (Mordor Intelligence, 2017) and that the Company are ( sic) filing additional patents to add a further layer of protection to the existing intellectual property portfolio to protect their ( sic) inventions and fully exploit the commercial potential.

A company is singular just like an illiterate PR agency, in this case the grossly overpaid retards at Walbrook PR.

This all sounds great but what the market wants to see are deals signed with big names that have a clear and material monetary value. Jam tomorrow - even if it could be massive zero calorie jam - will not wash any more. that is why the shares are unmoved on the day at 63p-65p.

Our conversations with Optibiotix lead us to expect the sort of announcements that investors are demanding soon;. that means deals with big name companies with an indication of value.

That will get the shares motoring and as we expect action soon our stance is, at up to 80p, BUY with a target to sell of 100p+

This article first appeared on HotStockRockets - to catch the next red hot share tip from the HotStockRockets team out shortly for just £5 click HERE

Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on OPTI


Comments are turned off for this article.

Site by Everywhen